This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Multiple Sclerosis
and you are
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Until now, there is no effective approach to stop the progression of multiple sclerosis and stimulate re-myelination. Autologous stem cell transplantation shows hope and is quickly developing as an alternative therapy. We propose the use of autologous bone marrow-derived specific stem cell populations and mesenchymal stem cell transplantation (BM-MSC) associated with immuno-modulation to treat patients with relapsing-remitting MS (RRMS).

Provided treatments

  • Biological: Stem Cell Transplantation
Tris trial is registered with FDA with number: NCT03069170. The sponsor of the trial is Stem Cells Arabia and it is looking for 50 volunteers for the current phase.
Official trial title:
Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis.